By following this multi-step process, the Open Targets Platform presents a ranked list of the targets associated with a disease or phenotype or vice versa. However, the prioritisation of targets sometimes requires the addition of extra information on how suitable these targets are for a given therapeutic hypothesis, for example how tractable the target is to modulation by different drug modalities (Figure 1C). To expand on target annotations that can assist in decision-making when reviewing a target list, an updated Open Targets tractability assessment for small molecules or antibodies is now included on our prioritisation view (27). We also provide information on target safety where available, including known side effects (28,29), safety risk information (30,31) and non-clinical experimental toxicity (32,33).
